TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04600323
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be given placebo at 0.5 mEq/kg-LBW/day for 12 months
Study: NCT05577182
Drug: INCA32459-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: solution for infusion
Study: NCT04609670
Drug: [14C]-ALXN2050
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of 200 milligrams (\~85 microcuries) \[14C\]-ALXN2050 will be administered orally.
Study: NCT05440383
Drug: KLH-2109
Normalized name: LINZAGOLIX CHOLINE 1 kg in 1 kg POWDER [KLH-2109 Choline]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT05785442
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.67 ml N/S 0.9% w/v administration subcutaneously once daily for 10 days (at least 4 days)
Study: NCT05654519
Drug: PENG/LFCN and QL Blocks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.25% injection
Study: NCT05992922
Drug: IC265 Ophthalmic Solution 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop will be instilled in each eye twice a day
Study: NCT05992922
Drug: Placebo Ophthalmic Solution (Vehicle)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop will be instilled in each eye twice a day
Study: NCT05273671
Drug: normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: will receive with a saline solution 10 min before the end of surgery
Study: NCT06722950
Drug: CAPEOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAPEOX: 130mg/m2 of oxaliplatin (D1, central intravenous drip for 2h (time window + 20min)), 1000mg/m2 of capecitabine tablets each time, orally, twice a day (D1-D14, morning and evening); repeat the CAPEOX chemotherapy regimen every 3 weeks.
Study: NCT06722950
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo：3 times a day (daily), taken with boiled water.
Study: NCT06722963
Drug: fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl used as an adjuvant to bupivacaine for intraperitoneal instillation during laparoscopic cholecystectomy, a dose is 50 micrograms is commonly added to the local anesthetic solution.
Study: NCT05147090
Drug: Placebo pills
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical in appearance to empagliflozin 10mg daily
Study: NCT05912192
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50mcg/dose of 0.9% sodium chloride One puff for each nostrils twice daily
Study: NCT06050824
Drug: Comparing Load and Concomitant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin - Omeprazole - nitazoxanide - doxycycline
Study: NCT05828485
Drug: MY008211A tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of MY008211A tablet was administered after fasting and high-fat, high-calorie feeding
Study: NCT06266832
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000mg/m2, po, bid, d1-14, Q3W
Study: NCT05741606
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules
Study: NCT06411314
Drug: Pimafucin® (natamycin) 100 mg vaginal suppositories
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 suppository once daily at bedtime for 6 days
Study: NCT05349071
Drug: physiological saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: a single preoperative dose of 250 mL of physiological saline 2 hours before surgery as a 30-minute infusion.
Study: NCT06240728
Drug: NPX887
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPX887 will be administered by IV infusion every 3 weeks until documented disease progression or participant withdrawal for up to 2 years
Study: NCT06466395
Drug: Hyper-CVAD
Normalized name: Hyper-Sal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by IV
Study: NCT05245968
Drug: Pimitespib
Normalized name: pimitespib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimitespib will be administered orally in 5 consecutive days followed by 2 days off treatment (QD 5) on an empty stomach at least 1 hour before or 2 hours after a meal. The doses in the Dose Escalation Part will be 80, 120 (starting dose), and 160 mg. The doses used in Arm A will be MTD or recommended dose (RD) based on the information, including the safety and the pharmacokinetics (PK) data in the Dose Escalation Part. In Expansion Part-B, pimitespib will be administered with the starting dose of 160 mg daily.
Study: NCT05666765
Drug: Isotretinoin ,silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mg/day isotretinoin for 3 months. 140 mg/day silymarin for 3 months. 20mg/day isotretinoin and 140mg/day silymarin for 3 months.
Study: NCT06454955
Drug: [68Ga] B7H3 Affibody-BCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: An affibody structure specifically targeting B7H3 was developed based on the B7H3 binding domain, and it was structurally optimized to yield a small molecular agent, B7H3 Affibody-BCH, suitable for nuclear medical diagnostic and therapeutic uses targeting B7H3. By labeling with the radioactive isotope \^68Ga, this agent can be used for PET/CT diagnosis of solid tumors.
Study: NCT05629741
Drug: CMTX-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm
Study: NCT05629741
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm
Study: NCT05909059
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Received IV on Days -5 to -3 before CAR T cell therapy
Study: NCT05221957
Drug: Iron(III)isomaltoside
Normalized name: Iron isomaltoside 1000
DrugBank: Iron isomaltoside 1000 (DB12208)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual weight and hemoglobin dependent dosage
Study: NCT05726227
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered subcutaneously once-weekly.
Study: NCT05570786
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subdermal implant-bioabsorbable placebo pellet (cholesterol)
Study: NCT06161441
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV Q3W
Study: NCT05245058
Drug: SPH5030 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPH5030 tablets orally once or twice daily.
Study: NCT06418789
Drug: High-dose chemotherapy (TI- 2 cycles, CE- 3 cycles )
Approvals — FDA: no, EMA: no, PMDA: no
Description: TI: Paclitaxel 200mg/m² on day 1, Ifosfamide 2000mg/m² daily from days 1 to 3 of 14-day cycle. G-CSF 10 micrograms/Kg SC daily day on days 6-14 day or until CD34 harvest. Leukapheresis will be performed starting on day 11 in case blood level of CD45+CD34+ above 20x10\^6/L is achieved.~CE: Carboplatin AUC=8 IV daily days -4 to -2, Etoposide 400mg/m\^2 IV daily days -4 to -2, autlologous stemm cell transplantation \>=2\*10\^6/Kg at day 0, GCSF support from day 4 until the recovery of neutrophils above 1\*10\^9/L.~Patients will receive two cycles of TI followed by 3 cycles of CE in case at least 6\*10\^6 CD34+ stem cells will be harvested.
Study: NCT05536596
Drug: Melatonin 10 MG Oral Tablet
Normalized name: melatonin 10 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B will receive the pharmacology treatment with 10 mg Melatonin. One capsule orally at night for 60 days.
Study: NCT05536596
Drug: Centrum
Normalized name: Centrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Groups A will receive the pharmacology treatment with 1.5 mg uridine triphosphate, 2.5 mg cytidine monophosphate and 1 mg hydroxycobalamin (Citoneuron). One capsule orally three times a day for 60 days as suggested by the manufacturer for patients with trauma - compressive peripheral neural disorders.
Study: NCT04490096
Drug: [11C]-PBR28
Approvals — FDA: no, EMA: no, PMDA: no
Description: A dose of ≤ 20 mCi (approximate range for most studies is anticipated to be 5-20 mCi) of \[11C\]-PBR28 will be administered by IV injection to the patient under the direct supervision of a Nuclear Medicine Authorized User. A lesser activity may be injected if, in the opinion of a nuclear medicine authorized user complete imaging data could be generated.~Subjects will undergo an approximately 90 minute dynamic PET/CT scan over the brain starting at approximately the same time as the \[11C\]-PBR-28 injection. Scans will be acquired using a Philips PET/CT time-of-flight Ingenuity scanner (Philips Healthcare, Cleveland, OH, USA). At the end of the dynamic imaging the participant will be allowed to get off the scanner.
Study: NCT05364164
Drug: CT-L01 12.5/1,000 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC tablet, 2 tablets at a time, oral administration, dosing after high-fat meal
Study: NCT05059262
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT06554301
Drug: placebo in treatment pulmonary aerterial hypertension
Approvals — FDA: no, EMA: no, PMDA: no
Description: On the basis of background treatment, the control group was given 10 mg of placebo tablets orally once a day for 12 weeks.
Study: NCT04980144
Drug: 0.1% hyaluronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% hyaluronate eye drops will be used to assess its usefulness in diabetic dry eye symptoms and compared to 3% Diquafosol tetrasodium eye drops.
Study: NCT04753879
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1. Patients will receive treatment Day 1-7 and Day 15-21 of each cycle (28 days).~2. Capecitabine (500 mg) will be administered orally twice a day on days 1-7 and 15-21 of each cycle (28 days).~3. Other Name: Xeloda
Study: NCT03123952
Drug: ABT-414
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-414 will be administered by intravenous infusion
Study: NCT05737199
Drug: MK-3475 (pembrolizumab)
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-3475 (pembrolizumab) 200mg IV every 3 weeks \[Q3W\] Treated for 2 years (35 cycles), or until PD, unacceptable toxicity, or study withdrawal.
Study: NCT06096571
Drug: Aterixen
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of R or T drug in each of 2 periods of the study in fasted conditions
Study: NCT06261827
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen-air mixture without NO after extubation after surgery for 5 days 2 times a day for 30 min
Study: NCT06261827
Drug: 200-ppm NO
Normalized name: caffeine 200 MG [No Doz]
Approvals — FDA: no, EMA: no, PMDA: no
Description: NO will be supplemented at 200-ppm concentration after surgery for 5 days 2 times a day for 30 min
Study: NCT06396208
Drug: Quadriphasic Estradiol valerate 1 - 3 mg/ Dienogest 2 - 3 mg (26/2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Completing a pack (28 pills) of Quadriphasic Estradiol valerate 1 - 3 mg/ Dienogest 2 - 3 mg (26/2), starting on day 7-9 of menstrual cycle
Study: NCT06396208
Drug: Ethinylestradiol (EE) 20 mcg/Gestodene 75 mcg (21/7)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Completing a pack (28 pills) of Ethinylestradiol (EE) 20 mcg/Gestodene 75 mcg (21/7), starting on day 7-9 of menstrual cycle
Study: NCT05097261
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (NaCl 0.9%) will be provided in the same type syringes and administered at the same infusion rate as the IMP (0.02 ml/kg/h to a maximum rate of 2.4 ml/h).
Study: NCT06175468
Drug: Formosa 1-Breath Free (NRICM101)
Normalized name: DICENTRA FORMOSA WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: After screening, the treatment of this study is divided into two groups: The treatment group is Formosa 1-Breath Free (NRICM101) granule 5g/bag, 3 times a day.
Study: NCT06175468
Drug: Placebo control drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: After screening, the treatment of this study is divided into two groups: The placebo control group is the placebo (dummy) 5g/bag, 3 times a day.
Study: NCT00004114
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05980546
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: This is a drug that is given as part of the analgesia and sedation regime. This drug is not the study intervention.
Study: NCT05866809
Drug: HK-660S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT05866809
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT04670471
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanil is a commonly used opioid in anaesthetic practice. It is a potent and fast-acting analgesic.
Study: NCT05868122
Drug: Acetaminophen/Naproxen Sodium Fixed Combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of Acetaminophen/Naproxen Sodium will be administered orally.
Study: NCT05868122
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered orally.
Study: NCT06722911
Drug: AG
Normalized name: AGP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive nab-paclitaxel 125 mg/m\^2 followed by gemcitabine 1,000 mg/m\^2 as one intravenous infusion over 30-40 minutes on days 1 and 8 of every 21-day cycle. Patients will receive six treatment cycles unless there is radiologic evidence of disease recurrence and unacceptable toxicity.
Study: NCT06723990
Drug: Neoadjuvant standard treatment for HER2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: NEOADJUVANT SETTING
Study: NCT06723990
Drug: Adjuvant standard treatment for HER2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADJUVANT SETTING
Study: NCT06523101
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two participants in each dose level will be randomized to receive placebo in a double-blind fashion.
Study: NCT04990804
Drug: Opioid Analgesic
Normalized name: OPIOID ANALGESICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be provided a prescription for low dose opioids for 5 days postoperatively (Hydrocodone/Acetaminophen 5/325mg or Oxycodone/Acetaminophen 5/325mg) to be taken every 6 hours as needed for pain. Refills may be provided (Hydrocodone/Acetaminophen 5/325mg or Oxycodone/Acetaminophen 5/325mg) if requested by the patient at the providers discretion. In addition, patients will also be prescribed Gabapentin 300mg q8 hours or Pregabalin 75mg twice daily and a muscle relaxer (Methocarbamol 750mg BID or Flexeril 5-10 mg TID) as needed for spasms. Alternative muscle relaxers (Metaxalone 800 mg TID or Tizanidine 2-6 mg TID) may be utilized if contraindications to methocarbamol and cyclobenzaprine exist.
Study: NCT04990804
Drug: Opioid-Free Postoperative Pain Regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive no opioids. Pain will be managed with Acetaminophen 1000mg q8 hours, Ketorolac 10mg every 6 hours (for 5 days), Gabapentin 300mg q8 hours or Pregabalin 75mg twice daily, and a muscle relaxer (Methocarbamol 750mg BID or Cyclobenzaprine 5-10 mg TID) all to be taken as scheduled for the first 2 weeks (except Ketorolac - 5 days) postoperatively as side effects permit. Other NSAIDS (Naprosyn 500 mg BID or Ibuprofen 800 mg TID) may be utilized if contraindications to Ketorolac exist. Famotidine (20mg BID) or Omeprazole (20mg daily) will be prescribed along with NSAIDS for GI prophylaxis. Alternative muscle relaxers (Metaxalone 800 mg TID or Tizanidine 2-6 mg TID) may be utilized if contraindications to methocarbamol and cyclobenzaprine exist.
Study: NCT06069895
Drug: NNC0113-6856
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNC0113-6856 will be administered as oral tablets.
Study: NCT06069895
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNC0113-6856 matching placebo will be administered as oral tablets.
Study: NCT04973670
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The same amount of NS containing only sivelestat sodium excipients
Study: NCT05086627
Drug: Capecitabine+Oxaliplatin
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients were treated with neoadjuvant chemotherapy with CapeOX (Capecitabine+Oxaliplatin).
Study: NCT05432466
Drug: Placebo BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo for ACER-002
Study: NCT06361108
Drug: YJ001 for Spray Use
Normalized name: Antibiotics for systemic use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granules for spray use; Preparation of Dosing Solution: Reconstitute with sterile water (50ml)
Study: NCT06361108
Drug: Placebo of YJ001 for Spray Use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive Ingredient: Sterile water; Preparation of Dosing Solution: 50ml Sterile water
Study: NCT05513807
Drug: Nicotinamide treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3g Nicotinamide orally (1g immediately pre transplant, then immediately 1g post-transplant after the recovery room and 1g 24 hours later)
Study: NCT05513807
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3g Placebo orally (1g immediately pre transplant, then immediately 1g post-transplant after the recovery room and 1g 24 hours later)
Study: NCT05274893
Drug: SYHX2011 and Abraxane®
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion, 260 mg/m\^2
Study: NCT06204835
Drug: RD-Cy7 fluorophore
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluorophore targeting ITGA6 that is overexpressed in HCC cells
Study: NCT05547516
Drug: Standard infusion chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard infusion chemotherapy (including gemcitabine, mitomycin, epirubicin, etc.), dissolved in 50mL normal saline or glucose, intravesical infusion chemotherapy, retained for 60min. Perfusion can be performed within 24 hours after surgery, and then once a week for a total of 8 times, and then once a month until 12 months after surgery
Study: NCT04265105
Drug: Standard Preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: inhaled SABA or Inhaled corticosteroid
Study: NCT05213767
Drug: TQB2916 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB2916 injection is a kind of Tumor necrosis factor receptor superfamily member 5 (CD40) agonist, which is a humanized immunoglobulinG2 (IgG2) monoclonal antibody targeting CD40. This product can bind to CD40 on target cells to activate downstream signaling pathways and generate anti-tumor immune responses. At the same time, it can promote the apoptosis of B-cell lymphoma Ramos cells.
Study: NCT04969991
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral formulation matched to the oral varespladib tablet
Study: NCT05338671
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive inferior alveolar nerve block injection following endodontic treatment.
Study: NCT05769465
Drug: disease modifying treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be enrolled if exposed to nusinersen, risdiplam, onasemnogene abeparvovec
Study: NCT06354816
Drug: Xylocaine 10% pump spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: First volunteers will undergo insertion of PIVC into the vessel of dorsum manus; 2-10 hours later: All volunteers will undergo insertion of PIVC into the forearm/cubita. Lidocaine spray 10 % serves as a local anesthesia is applied with a dispenser dispensing 0.1ml per pulse on the area of the skin, where the insertion of the PIVC is planned.~Exposure time is 2 min, timed with an hour glass; validated prior to the study by a stop watch. 0.5 ml (5 pulses) of 10% lidocaine spray (equals 50mg of lidocaine) are to be applied before insertion of a PIVC 18 Gauge.
Study: NCT06354816
Drug: Saline solution isotonic 0.9% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: First volunteers will undergo insertion of PIVC into the vessel at dorsum manus; 2-10 hours later: All volunteers will undergo insertion of PIVC into the forearm/cubita. Physiological saline solution serves as a placebo and is applied with a dispenser dispensing 0.1ml per pulse on the area of the skin, where the insertion of the PIVC is planned.~Exposure time is 2 min, timed with an hour glass; validated prior to the study by a stop watch. 0.5 ml (5 pulses) of 10% lidocaine spray (equals 50mg of lidocaine) are to be applied before insertion of a PIVC 18 Gauge.
Study: NCT05083117
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: It is anticipated that inhalation of 1 mg Placebo solution up to 14 days will result in a relatively lower systemic exposure in COVID-19 patients on oxygen therapy compared to that in healthy participants as COVID-19 patients tend to have impaired lung function of diffusive, restrictive, obstructive, or mixed origins.
Study: NCT05802121
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each patient will be instructed to take 6 placebo capsules per day for 3 months
Study: NCT05966688
Drug: SPR720
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple oral doses of SPR720 capsules.
Study: NCT05966688
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Multiple oral doses of azithromycin.
Study: NCT03127267
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment per os
Study: NCT05499052
Drug: REKOVELLE®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects must be treated according to the routine clinical practice and REKOVELLE® must be prescribed in accordance with the terms of the marketing authorisation of each participating country.~According to the label the REKOVELLE® dose should be based on a recent determination of body weight and a recent determination of Anti-Müllerian Hormone (AMH) (i.e. within the last 12 months) measured by the following diagnostic tests: ELECSYS AMH Plus immunoassay from Roche or alternatively the ACCESS AMH Advanced from Beckman Coulter or LUMIPULSE G AMH from Fujirebio.
Study: NCT04908787
Drug: BD0801
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects receive BD0801 , intravenously, d1, d15, q4w, Dosage form: injectable, Strength: 1.5 mg/kg
Study: NCT04908787
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects receive Placebo, intravenously, d1, d15, q4w, Dosage form: injectable, Strength: 1.5 mg/kg
Study: NCT04908787
Drug: doxorubicin liposome
Normalized name: Doxorubicin liposome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects receive doxorubicin liposome, intravenously, d1, , q4w, Dosage form: injectable, Strength: 40mg/m2